ASX ANNOUNCEMENT
6 November 2025

Disclosure of Long Equity Derivative Positions

Radiopharm Theranostics Limited ACN 647 877 889 (**Radiopharm** or the **Company**) advises that it has received the attached notice pursuant to the Australian Takeovers Panel Guidance Note 20 – Equity Derivatives.

Nathan Jong
Joint Company Secretary
Radiopharm Theranostics Limited

29 October 2025

Attn: Phillip Hains
Company Secretary
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street
Carlton South VIC 3053

Re: Disclosure under Takeovers Panel Guidance Note 20 – Equity Derivatives

Dear Phillip,

We refer to *Guidance Note 20: Equity Derivatives* (**GN20**) issued by the Australian Takeovers Panel. Terms not defined in this notice have the meaning given to them in GN20.

GN20 relevantly provides that the non-disclosure of long positions, including long equity derivative positions, may give rise to unacceptable circumstances. Point72 Asset Management, L.P. (**Point72**), as investment manager of Point72 Associates, LLC (the **Fund**), discloses the following information on behalf of the Fund, as at the date of this letter, under GN20.

Point72 has ceased to have a long equity derivative position of 5% or more (by reference to voting rights) in the ordinary shares of Radiopharm Theranostics Limited on 27 October 2025. As a result, Point72's aggregate long position (including any relevant interests in physical securities) is now below the 5% disclosure threshold contemplated by GN20.

Point72 consents to Radiopharm Theranostics Limited releasing the information contained in this formal disclosure to the ASX.

Identity of the taker:	Point72 Associates, LLC
Relevant security:	Ordinary shares in Radiopharm Theranostics Limited
Price (including reference price, strike price, option price etc as appropriate):	Not applicable
Entry date and number of securities to which the derivative relates:	Total number of securities to which derivatives relate as of 27 October 2025 is 136,511,480 ord shares
Type of derivative (e.g. contract for difference, cash settled put or call option):	Cash settled equity swap

Any material changes to information previously disclosed to the market:	Previous disclosure: total number of securities to which derivatives relate as of 21 January 2025 is 137,571,214 Ord shares
Relevant interest in the securities:	None
Long equity derivative positions held by the taker and its associates:	The Fund has no other associates with a long equity derivative position or relevant interest in the company
Short equity derivative positions that offset long positions	None
Short positions of more than 1% that have been acquired after a long position is disclosed, whether by notice or substantial holding notice.	None

Yours sincerely,



Vincent Tortorella
General Counsel and Chief Compliance Officer
Point72 Asset Management, L.P.+